Silence Therapeutics (SLN) Expected to Announce Earnings on Wednesday

Silence Therapeutics (NASDAQ:SLN) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect Silence Therapeutics to post earnings of ($0.16) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Silence Therapeutics Price Performance

SLN opened at $4.85 on Monday. The business has a 50 day simple moving average of $5.40 and a 200-day simple moving average of $11.34. The stock has a market capitalization of $145.16 million, a P/E ratio of -3.09 and a beta of 1.08. Silence Therapeutics has a 12 month low of $4.06 and a 12 month high of $27.72.

Analyst Ratings Changes

SLN has been the subject of several recent research reports. The Goldman Sachs Group dropped their price target on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research report on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Chardan Capital restated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets decreased their price objective on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.